Page 5 - CUA KIDNEY CANCER HANDBOOK 2020
P. 5
Table of contents
Introduction 5
Management of Locally Advanced Kidney Cancer 7
Management Algorithm 7
Management of Surgical Candidates 7
Management of Patients who are Medically or Surgically Inoperable 10
Management of Advanced/Metastatic
Kidney Cancer 11
Patient Identification and Evaluation 11
Risk Stratification 11
Management Algorithm 13
Untreated/First-line Options: Clear-cell Carcinoma 15
Second-line (or Later) Options: Clear-cell Carcinoma 19
Considerations for Baseline Assessment and Monitoring Patients
During Therapy 22
Role of Cytoreductive Nephrectomy 24
Recommendations for Cytoreductive Nephrectomy 24
Post-Nephrectomy Management 25
Key Trials 27
First-line Treatment of Advanced/Metastatic Renal Cell Carcinoma 27
KEYNOTE-426 (axitinib + pembrolizumab vs. sunitinib) 28
CheckMate 214 (ipilimumab + nivolumab vs. sunitinib) 29
JAVELIN Renal 101 (axitinib + avelumab vs. sunitinib) 30
Second-line (or Later) Treatment of Advanced/Metastatic Renal Cell Carcinoma 31
CheckMate 025 (nivolumab vs. everolimus) 32
METEOR (cabozantinib vs. everolimus) 33
AXIS (axitinib vs. sorafenib) 34
Lenvatinib + everolimus 35
Cytoreductive Nephrectomy 37
CARMENA 38
SURTIME 39
Conference Highlights 41
KEYNOTE-426 (axitinib + pembrolizumab vs. sunitinib) 41
OMNIVORE (nivolumab-ipilimumab response-based study) 42
HCRN GU16-260 (nivolumab-ipilimumab response-based study) 42
Oligoprogression – Stereotactic RT Study 43
Immune Checkpoint Inhibitors in Older Adults – IMDC Analysis 44
Continued on next page
Practical Approaches to Managing Advanced Kidney Cancer 3
